ethics committee SOP – Clinical Research Made Simple https://www.clinicalstudies.in Trusted Resource for Clinical Trials, Protocols & Progress Thu, 07 Aug 2025 15:52:32 +0000 en-US hourly 1 https://wordpress.org/?v=6.9.1 SOP for EC/IRB Continuing Review and Renewals https://www.clinicalstudies.in/sop-for-ec-irb-continuing-review-and-renewals/ Thu, 07 Aug 2025 15:52:32 +0000 ]]> https://www.clinicalstudies.in/sop-for-ec-irb-continuing-review-and-renewals/ Read More “SOP for EC/IRB Continuing Review and Renewals” »

]]>
SOP for EC/IRB Continuing Review and Renewals

{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.Clinicalstudies.in/SOP-for-EC-IRB-Continuing-Review-and-Renewals”
},
“headline”: “SOP for Ethics Committee and IRB Continuing Review and Renewals”,
“description”: “This SOP outlines the regulatory-compliant process for EC/IRB continuing review and renewals to maintain ethical oversight of clinical trials, aligned with ICH GCP, FDA, EMA, CDSCO, and WHO guidelines.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-26”,
“dateModified”: “2025-08-26”
}

Standard Operating Procedure for EC/IRB Continuing Review and Renewals

Department Clinical Research
SOP No. CR/ETH/007/2025
Supersedes NA
Page No. 1 of 21
Issue Date 26/08/2025
Effective Date 01/09/2025
Review Date 01/09/2026

Purpose

The purpose of this SOP is to describe the process for conducting Ethics Committee (EC) and Institutional Review Board (IRB) continuing reviews and renewals of clinical trials. This ensures ongoing ethical oversight, participant protection, and compliance with ICH-GCP, WHO, FDA, EMA, and CDSCO regulatory requirements.

Scope

This SOP applies to all clinical research staff, investigators, regulatory affairs personnel, and quality assurance officers involved in the preparation, submission, and follow-up of EC/IRB continuing review and renewal applications for clinical trials.

Responsibilities

  • Principal Investigator (PI): Prepares progress reports and renewal documents for submission to EC/IRB.
  • Regulatory Affairs Manager: Coordinates submissions and ensures compliance with regional requirements.
  • Clinical Research Associate (CRA): Collects site-level data and ensures accuracy of reports.
  • Quality Assurance Officer: Reviews documents for completeness and compliance with applicable guidelines.
  • Head of Clinical Research: Approves submissions before dispatch to EC/IRB.

Accountability

The Regulatory Affairs Head is accountable for ensuring that continuing review and renewal applications are submitted on time, complete, and compliant. Failure to maintain approvals may result in trial suspension or regulatory non-compliance.

Procedure

1. Identification of Renewal Requirement
Determine the renewal due date based on EC/IRB initial approval letter.
Notify PI and study team at least 60 days before renewal deadline.

2. Preparation of Renewal Package
Include protocol progress report, enrollment status, safety summary (AE/SAE reports), deviations, amendments since last approval, and updated Investigator’s Brochure if applicable.
Ensure all documents are updated and signed by responsible personnel.

3. Internal Review
QA reviews renewal package for completeness.
Head of Clinical Research reviews and approves the package.

4. Submission to EC/IRB
Submit renewal package in electronic or paper form as per EC/IRB requirements.
File proof of submission in Regulatory Communication Log.

5. Approval Tracking
Maintain EC/IRB Renewal Tracker with submission and approval dates.
Follow up until approval is received.

6. Post-Approval Implementation
Communicate approval to trial sites and sponsor.
Implement EC/IRB conditions, if any, prior to continuing the trial.

Abbreviations

  • SOP: Standard Operating Procedure
  • EC: Ethics Committee
  • IRB: Institutional Review Board
  • PI: Principal Investigator
  • CRA: Clinical Research Associate
  • QA: Quality Assurance
  • AE: Adverse Event
  • SAE: Serious Adverse Event
  • TMF: Trial Master File

Documents

  1. EC/IRB Renewal Checklist (Annexure-1)
  2. EC/IRB Renewal Tracker (Annexure-2)
  3. Regulatory Communication Log (Annexure-3)

References

  • ICH E6(R2) – Good Clinical Practice
  • US FDA 21 CFR Part 56 – IRB Requirements
  • EMA Clinical Trial Regulation (EU No. 536/2014)
  • WHO Guidelines for Ethics Committees
  • CDSCO Clinical Trial Rules, India (2019)

Version: 1.0

Approval Section

Prepared By Rajesh Kumar, Regulatory Affairs Specialist
Checked By Sunita Reddy, QA Officer
Approved By Dr. Anil Sharma, Head of Clinical Research

Annexures

Annexure-1: EC/IRB Renewal Checklist

Document Included (Yes/No) Remarks
Protocol Progress Report Yes Covering Jan–Jun 2025
Safety Summary Yes All SAEs included
Updated Investigator’s Brochure Yes Version 5.0 submitted

Annexure-2: EC/IRB Renewal Tracker

Submission Date EC/IRB Name Approval Date Status Remarks
05/09/2025 Metro Ethics Committee 25/09/2025 Approved Annual renewal granted

Annexure-3: Regulatory Communication Log

Date Authority Query Response Responsible Person
15/09/2025 Metro EC Provide SAE follow-up details Submitted updated safety table Rajesh Kumar

Revision History

Revision Date Revision No. Revision Details Reason for Revision Approved By
26/08/2025 00 Initial version New SOP creation Head, Clinical Research

For more SOPs visit: Pharma SOP

]]>
Preparing a Complete Ethics Committee Submission Package https://www.clinicalstudies.in/preparing-a-complete-ethics-committee-submission-package/ Sun, 15 Jun 2025 12:44:26 +0000 https://www.clinicalstudies.in/preparing-a-complete-ethics-committee-submission-package/ Read More “Preparing a Complete Ethics Committee Submission Package” »

]]>
Preparing a Complete Ethics Committee Submission Package

How to Prepare a Complete Ethics Committee Submission Package for Clinical Trials

Before initiating any clinical trial, obtaining Ethics Committee (EC) or Institutional Review Board (IRB) approval is mandatory. A complete and well-organized EC submission package is critical to secure timely approval and begin site activation. This tutorial provides a step-by-step guide for preparing and compiling an EC submission package in accordance with GCP and regulatory requirements.

Why a Complete EC Submission is Crucial:

Incomplete or non-compliant EC submissions lead to delays, queries, or outright rejections. A thorough package ensures:

  • Compliance with ICH-GCP and national regulations
  • Faster review and fewer clarification requests
  • Transparency and ethical oversight for participant protection

Whether submitting to CDSCO registered ECs in India or to an international IRB, proper preparation is essential.

Key Documents in an Ethics Committee Submission Package:

The exact list of documents may vary by region, but a standard package should include:

  1. Cover Letter: Clearly outline what is being submitted and request approval
  2. Clinical Trial Protocol: Complete, signed copy including version number and date
  3. Investigator’s Brochure (IB): For investigational products; includes safety and efficacy data
  4. Informed Consent Form (ICF): All language versions, including assent (if applicable)
  5. Case Report Form (CRF) sample: For EC awareness of data to be collected
  6. Ethics Committee Application Form: As per institutional or national template
  7. Protocol Synopsis: Brief summary of objectives, design, and endpoints
  8. Investigator CV: Signed and dated, showing GCP training and qualifications
  9. Site SOP list: Relevant to trial conduct and documentation
  10. Insurance Certificate: For participant injury or trial-related compensation
  11. Product Label or Package Insert: Especially for marketed comparators
  12. EC Fee Receipt: If applicable

Maintain document version control and consistency throughout. Refer to pharma SOP templates for standard formats and cover letter samples.

Formatting and Compilation Best Practices:

  • Organize documents in the order prescribed by the EC or regulatory body
  • Use clear labels, dividers, and bookmarks (for electronic submissions)
  • Highlight changes in revised protocols or consent forms using track changes
  • Include a checklist to confirm submission completeness

For e-submissions, ensure PDF compatibility, file size limits, and digital signature requirements are met.

Timeline for Ethics Committee Submissions:

Plan EC submissions in advance to accommodate the following stages:

  1. Pre-submission: Assemble documents, collect signatures, and verify data
  2. Initial submission: Submit before the EC’s monthly/bi-weekly meeting deadline
  3. Review period: Typically 2–6 weeks depending on EC SOP
  4. Clarifications (if needed): Respond promptly to EC queries
  5. Approval letter issuance: Includes approval number, date, and conditions

Missing any of these stages can delay site activation and first patient enrollment.

Common Errors in EC Submission and How to Avoid Them:

  • Error: Mismatched protocol and ICF version numbers

    Fix: Double-check version control across all documents
  • Error: Missing insurance or GCP training certificates

    Fix: Include updated, signed copies for all investigators
  • Error: Incomplete translation of consent documents

    Fix: Submit all local language versions with back-translation certificates
  • Error: Omitting site-specific data or address on forms

    Fix: Customize templates as per site or EC requirements

Use tools from StabilityStudies.in and trial SOP manuals to stay audit-ready.

Role of the Principal Investigator (PI):

The PI is responsible for ensuring:

  • Accuracy and completeness of the EC package
  • All investigators are trained and have signed documents
  • Follow-up with the EC for queries and approvals
  • Document retention in the Investigator Site File (ISF)

The PI must also sign the submission cover letter and application forms.

Submitting Amendments to the Ethics Committee:

Any change to protocol, ICF, PI, or study documents post-approval requires amendment submission. Include:

  • Amendment cover letter
  • Tracked and clean versions of revised documents
  • Updated synopsis (if applicable)
  • Rationale for change
  • Previous EC approval letter (if required)

Never implement changes until EC amendment approval is received, unless required for urgent safety reasons.

Ethics Committee Communication and Query Management:

  • Maintain a log of all EC correspondence (email, letters, meeting notes)
  • Assign a single point-of-contact for communications
  • Respond to queries within the EC-specified timeline
  • Document all responses in the ISF

Refer to pharma regulatory requirements for IRB interaction SOPs.

Conclusion:

A well-prepared Ethics Committee submission package is the first step toward ethical, compliant, and timely clinical trial initiation. By organizing documents, adhering to regulatory formats, and maintaining transparency with ECs, clinical trial professionals can streamline approval timelines and maintain audit readiness. Use submission checklists, trained staff, and site-specific SOPs to ensure each EC package meets the highest standards of quality and ethics.

]]>